• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酒精摄入对氟伐他汀药代动力学、疗效及安全性的影响。

Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.

作者信息

Smit J W, Wijnne H J, Schobben F, Sitsen A, de Bruin T W, Erkelens D W

机构信息

Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.

出版信息

Am J Cardiol. 1995 Jul 13;76(2):89A-96A. doi: 10.1016/s0002-9149(05)80026-8.

DOI:10.1016/s0002-9149(05)80026-8
PMID:7604808
Abstract

Alcohol consumption is known to have beneficial effects on cardiac mortality, probably by increasing high density lipoprotein cholesterol (HDL-C). Alcohol also increases triglycerides and, in some studies, total cholesterol and low density lipoprotein cholesterol (LDL-C). Nothing is known, however, of the effects of alcohol on the pharmacokinetics and efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Consequently, 2 studies have been carried out to determine the effects of alcohol consumption on the pharmacokinetics and efficacy of the HMG-CoA reductase inhibitor fluvastatin. Firstly, the effects of acute alcohol consumption on a single, oral 40 mg dose of fluvastatin were examined in a reference-controlled, randomized, crossover study in 10 healthy volunteers. Measurements were made after ingestion of 70 g of ethanol diluted to 20% with lemonade and, following a 7-day period, after ingestion of lemonade alone (reference). The half-life (t1/2) of a single dose of fluvastatin was significantly reduced by acute alcohol consumption compared with reference, whereas the area under the time-concentration curve (AUC), peak concentration (Cmax), and time to peak concentration (tmax) did not differ from the reference group. The lipid profile, measured 8 hr after administration, did not differ significantly from baseline in the reference group, apart from a slight reduction in apolipoprotein (apo)-AI. Triglyceride levels increased with alcohol, probably due to impaired fatty acid oxidation. Surprisingly, total cholesterol and LDL-C fell significantly, possibly due to altered pharmacokinetics, as reflected by the lower t1/2.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

已知饮酒对心脏死亡率有有益影响,可能是通过增加高密度脂蛋白胆固醇(HDL-C)来实现的。酒精还会增加甘油三酯,并且在一些研究中,还会增加总胆固醇和低密度脂蛋白胆固醇(LDL-C)。然而,关于酒精对3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂的药代动力学和疗效的影响却一无所知。因此,开展了两项研究来确定饮酒对HMG-CoA还原酶抑制剂氟伐他汀的药代动力学和疗效的影响。首先,在一项参考对照、随机、交叉研究中,对10名健康志愿者口服40mg单剂量氟伐他汀后急性饮酒的影响进行了研究。在摄入用柠檬水稀释至20%的70g乙醇后进行测量,并在7天后,仅摄入柠檬水(参考)后进行测量。与参考组相比,急性饮酒显著降低了单剂量氟伐他汀的半衰期(t1/2),而时间-浓度曲线下面积(AUC)、峰浓度(Cmax)和达峰时间(tmax)与参考组无差异。给药8小时后测量的血脂谱与参考组的基线相比无显著差异,除了载脂蛋白(apo)-AI略有降低。甘油三酯水平随酒精摄入而升高,可能是由于脂肪酸氧化受损。令人惊讶的是,总胆固醇和LDL-C显著下降,可能是由于药代动力学改变,这由较低的t1/2反映出来。(摘要截断于250字)

相似文献

1
Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.酒精摄入对氟伐他汀药代动力学、疗效及安全性的影响。
Am J Cardiol. 1995 Jul 13;76(2):89A-96A. doi: 10.1016/s0002-9149(05)80026-8.
2
Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.氟伐他汀对高胆固醇血症患者中密度脂蛋白(残粒)及其他脂蛋白水平的影响。
Am J Cardiol. 1995 Jul 13;76(2):129A-135A. doi: 10.1016/s0002-9149(05)80035-9.
3
Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.氟伐他汀与考来烯胺治疗后含载脂蛋白B血浆脂蛋白颗粒水平的变化。欧洲氟伐他汀研究组。
Am J Cardiol. 1995 Jul 13;76(2):65A-70A. doi: 10.1016/s0002-9149(05)80021-9.
4
Effects of alcohol and fluvastatin on lipid metabolism and hepatic function.酒精和氟伐他汀对脂质代谢及肝功能的影响。
Ann Intern Med. 1995 May 1;122(9):678-80. doi: 10.7326/0003-4819-122-9-199505010-00006.
5
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.氟伐他汀(一种全合成的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂)的疗效。FLUENT研究组。氟伐他汀长期扩展试验。
Am J Cardiol. 1995 Jul 13;76(2):37A-40A. doi: 10.1016/s0002-9149(05)80014-1.
6
Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.氟伐他汀对中国高胆固醇血症患者血脂谱和载脂蛋白的影响。
Am J Cardiol. 1995 Jul 13;76(2):136A-139A. doi: 10.1016/s0002-9149(05)80036-0.
7
Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.氟伐他汀对接受环孢素治疗的肾移植患者安全降低致动脉粥样硬化血脂的作用。
Am J Cardiol. 1995 Jul 13;76(2):102A-106A. doi: 10.1016/s0002-9149(05)80028-1.
8
A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.氟伐他汀对接受环孢素治疗的肾移植患者高胆固醇血症安全性和有效性的初步报告。
Am J Cardiol. 1995 Jul 13;76(2):107A-109A. doi: 10.1016/s0002-9149(05)80029-3.
9
Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.氟伐他汀长期治疗家族性高胆固醇血症的临床疗效
Am J Cardiol. 1995 Jul 13;76(2):47A-50A. doi: 10.1016/s0002-9149(05)80016-5.
10
Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.氟伐他汀单药治疗及与考来烯胺联合使用的长期疗效(一项为期156周的多中心研究)。法荷氟伐他汀研究组。
Am J Cardiol. 1995 Jul 13;76(2):41A-46A. doi: 10.1016/s0002-9149(05)80015-3.

引用本文的文献

1
Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases.系统评价和荟萃分析方案:他汀类药物作为免疫调节剂对慢性病成人炎症标志物的影响。
BMJ Open. 2020 Aug 13;10(8):e039034. doi: 10.1136/bmjopen-2020-039034.
2
Clinical pharmacokinetics of fluvastatin.氟伐他汀的临床药代动力学
Clin Pharmacokinet. 2001;40(4):263-81. doi: 10.2165/00003088-200140040-00003.
3
Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of scottish men with 21 years of follow up.
饮酒与全因死亡率、冠心病和中风:对苏格兰男性进行21年随访的前瞻性队列研究结果
BMJ. 1999 Jun 26;318(7200):1725-9. doi: 10.1136/bmj.318.7200.1725.
4
Pharmacokinetic interactions between alcohol and other drugs.酒精与其他药物之间的药代动力学相互作用。
Clin Pharmacokinet. 1997 Aug;33(2):79-90. doi: 10.2165/00003088-199733020-00001.
5
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.HMG-CoA还原酶抑制剂的药效学与药代动力学。异同点。
Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005.